icon-folder.gif   Conference Reports for NATAP  
 
  17th European AIDS Conference
November 6-9
2019, Basel
Back grey_arrow_rt.gif
 
 
 
Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
 
 
  10th International Workshop on HIV and Aging, October 10-11, 2019, New York
Reported by Jules Levin
 
Parul Patel,1Susan L. Ford,2Herta Crauwels,3Kelong Han,4Stefaan Rossenu,3MartineNeyens,3Yu Lou,2Sandy Griffith,1Krischan J. Hudson,1David A. Margolis,1Mark Baker,5Peter E. Williams,3William R. Spreen1 1ViiV Healthcare, Research Triangle Park, NC; 2GlaxoSmithKline, Research Triangle Park, NC; 3Janssen Research and Development, Beerse, Belgium; 4GlaxoSmithKline, Collegeville, PA; 5ViiVHealthcare, Nyon, Switzerland

1202191

1202192

1202193

1202194

1202195